Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 13 Show results per page	View Search Criteria \| Help With Results


1.		Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				06-2247 NCT00442533


2.		Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				MIP-IB12 NCT00458952


3.		Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				CTCT 06-11 NCT00493883

Last Modified: 10/6/2008 First Published: 10/25/2004


4.		Phase II Study of Intrahepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion in Patients With Unresectable Primary or Metastatic Liver Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 and over				NCI				NCI-04-C-0273 NCI-6332, DELCATH-G990039, NCT00096083

Last Modified: 7/17/2007 First Published: 3/24/2005


5.		Phase II Pilot Study of Targeted Radiotherapy Using Iodine I 131 Metaiodobenzylguanidine Combined With Arsenic Trioxide in Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Chromaffin Cell Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 1				Other				MSKCC-04148 NCT00107289


6.		TheraSphere for the Treatment of Liver Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				G040148 NCT00511862


7.		Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				PTK787/ZK222584 LSU IRB-6355, NCT00590343


8.		Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				2006-0954 NCT00607113

Last Modified: 12/13/2007 First Published: 11/1/2002


9.		Phase I Study of Yttrium Y 90-DOTA-tyr3-Octreotide in Children With Advanced or Refractory Somatostatin Receptor-Positive Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				2 to 25				NCI				UIHC-200008086 NCI-V02-1710, NCT00049023, 200008086


10.		Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				N05-10564 NCT00314925

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute